GT Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Michael Breen

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi	36.5%
CEO görev süresi	2.7yrs
CEO sahipliği	1.3%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Michael Breen'un ücretlendirmesi GT Biopharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	n/a	n/a	-US$10m
Dec 31 2023	US$2m	US$556k	-US$8m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$15m
Mar 31 2023	n/a	n/a	-US$16m
Dec 31 2022	US$2m	US$493k	-US$21m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$32m
Mar 31 2022	n/a	n/a	-US$34m
Dec 31 2021	US$3m	US$63k	-US$58m

Tazminat ve Piyasa: Michael 'nin toplam tazminatı ($USD 1.53M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 653.78K ).

Tazminat ve Kazançlar: Michael 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Michael Breen (61 yo)

2.7yrs

Görev süresi

US$1,525,834

Tazminat

Mr. Michael Martin Breen serves as Interim Chief Executive Officer at GT Biopharma, Inc. since March 02, 2022. Mr. Breen serves as an Executive Chairman at GT Biopharma, Inc. since November 08, 2021 and se...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Breen	Interim CEO & Executive Chairman	3.8yrs	US$1.53m	1.28% $ 84.8k
Charles Casamento	Independent Director	1.5yrs	US$218.33k	0% $ 0
Rajesh Shrotriya	Independent Director	3.8yrs	US$586.00k	0% $ 0
Bruce Wendel	Independent Vice Chairman	4yrs	US$586.00k	0.53% $ 34.9k
Lisa Haile	Scientific Advisor	no data	Veri yok	Veri yok
Philip Werthman	Chairman of Science Advisory Board	4.1yrs	Veri yok	Veri yok
Jeffrey Miller	Scientific Advisor	no data	Veri yok	Veri yok
Samir Taneja	Member of Scientific & Medical Advisory Board	4.1yrs	Veri yok	Veri yok
Arjun Balar	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

74.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GTBP 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

GT Biopharma Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

GT Biopharma, Inc. Announces CFO Changes

GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024

GT Biopharma, Inc. Announces Board Changes

Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee

High number of new and inexperienced directors

Recent updates

GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Announces CFO Changes

New major risk - Shareholder dilution

GT Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $3.219 million.

New major risk - Financial position

GT Biopharma, Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Share price stability

GT Biopharma Announces 1 for 30 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Nasdaq Listing Qualifications Department Determines the GT Biopharma's Eligibility for an Additional 180 Calendar Day Period, or Until February 20, 2024, to Regain Compliance

New major risk - Revenue and earnings growth

New major risk - Market cap size

GT Biopharma, Inc. Announces Board Changes

We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

Gt Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

GT Biopharma, Inc. Announces Gregory Berk, President of Research & Development and Chief Medical Officer, Is no Longer Employee

Price target decreased to US$4.00

High number of new and inexperienced directors

GT Biopharma files for $150M mixed shelf offering

We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

Gt Biopharma, Inc. Affirms Manufacturing Timeline for Lead Investigational Asset GTB-3650

GT Biopharma GAAP EPS of -$0.10 beats by $0.07

GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell 3000E Index

GT Biopharma, Inc. Appoints Alan L. Urban to Fill Vacant Seat on Board

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

GT Biopharma, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$17.33

High number of new and inexperienced directors

GT Biopharma, Inc. Announces CEO Changes

GT Biopharma, Inc Appoints Manu Ohri as Chief Financial Officer

Price target decreased to US$17.33

GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

Price target increased to US$25.33

High number of new and inexperienced directors

GT Biopharma Announces Updated Positive Safety Data from Phase 1 GTB-3550 Monotherapy Trike Trial an Investigational Immunotherapy for Refractory Cancers to Be Presented At ESMO Congress 2021

GT Biopharma, Inc. Advances GTB-3650, a Second-Generation Tri-Specific Killer Engager -TriKE®, Into IND-Enabling Studies

GT Biopharma, Inc. announced delayed 10-Q filing

GT Biopharma Provides Second Quarter 2021 Business Update

Price target increased to US$25.33

GT Biopharma Announces Interim GTB-3550 Trike Monotherapy Clinical Trial Results

Getting To Know GT Biopharma

GT Biopharma, Inc. Announces Update on the Commencement of the GTB-3550 Trike Monotherapy Phase 2 Clinical Trial and Solid Tumor Trike Product Candidates

GT Biopharma names Gregory Berk Chief Medical Officer

GT Biopharma, Inc. announced delayed annual 10-K filing

GT Biopharma, Inc. Updates Interim GTB-3550 Trike™ Clinical Trial Results

GT Biopharma, Inc. Announces Preclinical Results For Its ROR1 TriKE™ As A Treatment For Prostate Cancer

GT Biopharma, Inc. Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE, a Novel NK Cell Therapeutic Cancer Treatment

Gt Biopharma, Inc. Sign an Expanded GMP Manufacturing Agreement with Cytovance Biologics

GT Biopharma, Inc. has completed a Composite Units Offering in the amount of $23.65 million.

GT Biopharma, Inc. Announces Board Changes

GT Biopharma Announces Eighth Patient Begins Treatment of GTB-3550

GT Biopharma, Inc. Announces TriKE™ for the Treatment of Breast and GI Cancers

Gt Biopharma, Inc. and Cytovance Reaches Agreement for License Rights to Use Certain Bacterial and Mammalian Cell Lines and for GMP Manufacturing Services Performed to Date Regarding the Company's Trike™ Product Candidates

Dr. Greg Berk, M.D. Joins Board of Directors of GT Biopharma, Inc

GT Biopharma, Inc. Appoints Michael Handelman as Chief Financial Officer

GT Biopharma, Inc. Announces Advisory Board Appointments

GT Biopharma, Inc. announced that it has received $0.25 million in funding

GT Biopharma, Inc. announced that it has received $5.607 million in funding

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş